Telesair received FDA clearance
By HME News Staff
Updated 9:00 AM CDT, Thu October 19, 2023
IRVINE, Calif. – Telesair has received U.S. Food and Drug Administration clearance to market its Bonhawa High Flow Oxygen Therapy (HFOT) system, which is designed to treat patients with respiratory insufficiency. Bonhawa gives health care providers and their patients in the U.S. and worldwide an extended flow range, a streamlined disinfection process and an intuitive touchscreen. “The best-in-class Bonhawa system greatly improves patient care while enhancing efficiency for clinicians,” said Bryan Liu, PhD, CEO of Telesair. “It represents a significant milestone in that it is a more cost-effective, user-friendly option for treating respiratory conditions. Our team has decades of experience developing and commercializing revolutionary respiratory solutions and collaborated to create this efficient, easy-to-use system.” Telesair’s introduction of its lightweight oxygen therapy system to the U.S. further expands the company’s existing market access that includes Europe, Latin America, Asia and the Middle East.
Comments